- Home
- ITRM vs CASI Comparison
ITRM vs CASI Comparison
Compare ITRM & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- CASI
- Stock Information
- Founded
- ITRM 2015
- CASI 1991
- Country
- ITRM Ireland
- CASI China
- Employees
- ITRM N/A
- CASI N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- CASI Health Care
- Exchange
- ITRM Nasdaq
- CASI Nasdaq
- Market Cap
- ITRM 37.7M
- CASI 33.4M
- IPO Year
- ITRM 2018
- CASI 1996
- Fundamental
- Price
- ITRM $1.30
- CASI $1.98
- Analyst Decision
- ITRM Strong Buy
- CASI Strong Buy
- Analyst Count
- ITRM 1
- CASI 1
- Target Price
- ITRM $5.00
- CASI $4.00
- AVG Volume (30 Days)
- ITRM 364.7K
- CASI 15.4K
- Earning Date
- ITRM 05-12-2025
- CASI 05-13-2025
- Dividend Yield
- ITRM N/A
- CASI N/A
- EPS Growth
- ITRM N/A
- CASI N/A
- EPS
- ITRM N/A
- CASI N/A
- Revenue
- ITRM N/A
- CASI $28,537,000.00
- Revenue This Year
- ITRM N/A
- CASI $66.12
- Revenue Next Year
- ITRM $150.10
- CASI $51.37
- P/E Ratio
- ITRM N/A
- CASI N/A
- Revenue Growth
- ITRM N/A
- CASI N/A
- 52 Week Low
- ITRM $0.81
- CASI $1.88
- 52 Week High
- ITRM $3.02
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- ITRM 56.35
- CASI 45.04
- Support Level
- ITRM $1.01
- CASI $1.91
- Resistance Level
- ITRM $1.42
- CASI $2.14
- Average True Range (ATR)
- ITRM 0.09
- CASI 0.20
- MACD
- ITRM 0.03
- CASI 0.00
- Stochastic Oscillator
- ITRM 73.17
- CASI 24.49
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.